ArticleInfection and drug resistance2026
Development and Clinical Evaluation of an LC-MS/MS Method for the Determination of Isoniazid in Cerebrospinal Fluid from Tuberculous Meningitis.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Isoniazid (INH), a first-line anti-tuberculosis agent, exhibits variable cerebrospinal fluid (CSF) penetration owing to NAT2 genetic polymorphisms. This study developed an LC-MS/MS method to quantify INH in the human CSF for therapeutic drug monitoring in patients with tuberculous meningitis. Methods: The LC-MS/MS method developed and validated in this study includes linearity, sensitivity, accuracy, precision, extraction recovery, matrix effect, and stability evaluations, all of which meet the standards for bioanalytical method validation. This method was applied to a real-world prospective observational study to compare CSF trough concentrations of INH between patients receiving conventional anti-tuberculosis therapy and those receiving conventional therapy combined with intrathecal INH injection, and a pharmacokinetic study was conducted in one TBM patient. Results: The validated LC‑MS/MS method achieved a total run time of 3.5 min, demonstrated linearity over the range of 5-4000 ng/mL, and had an LLOQ of 5 ng/mL, with all validation parameters meeting acceptance criteria. In the clinical cohort, the median CSF trough concentration of INH was significantly higher in the intrathecal therapy group (1130.00 ng/mL, N=117) than in the conventional therapy group (155.00 ng/mL, N=45, P<0.001). Target attainment rates at ≥120 ng/mL and ≥250 ng/mL were also significantly greater in the intrathecal group (84.62% and 77.78%, respectively) versus the conventional group (57.78% and 35.56%, both P<0.001). Pharmacokinetic analysis in a TBM patient after intrathecal INH administration revealed a T Conclusion: A sensitive and reliable LC-MS/MS method was successfully developed and validated for quantification of INH in human CSF. This study confirms that intrathecal administration of INH can significantly increase drug concentrations in the CSF of TBM patients, providing methodological support and preliminary clinical evidence for optimizing treatment strategies in TBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.